Piper Sandler reiterates Overweight rating on Alkermes stock ahead of trial
PositiveFinancial Markets

Piper Sandler has reaffirmed its Overweight rating on Alkermes stock as the company approaches a significant trial. This endorsement is crucial as it reflects confidence in Alkermes' potential to perform well in the market, especially with the upcoming trial that could impact its future. Investors often look for such ratings to gauge the viability of their investments, making this news particularly relevant for those tracking Alkermes.
— Curated by the World Pulse Now AI Editorial System